Principal Investigator
Robert Ritch, M.D.
Objective
To detect differences in the iris thickness in patients on systemic alpha adrenergic blockers using UBM and SL-OCT
Eligibility
Patients on Flomax and that have used it in the past (for at least 6 months). Exclusion on Patients with any disease that could change iris morphology (uveitis, PDS, XFS, trauma...) or previous intraocular surgery.
Enrollment Status:
Closed to Enrollment
